Markets:

Overview

News

Currencies

International

Treasuries

Esperion Therapeutics, Inc. - Common Stock (NQ:ESPR)

3.110 +1.110 (+55.50%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Esperion Therapeutics, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Why UiPath Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗

March 16, 2023

Gainers ThermoGenesis Holdings, Inc. (NASDAQ: THMO) rose 38.9% to $5.82 in pre-market trading. ThermoGenesis shares jumped around 99% on Wednesday after the company announced the roll out of ReadyStart...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

March 16, 2023

It's time for another dive into the biggest pre-market stock movers as we go over all the latest news for Thursday morning!

Via InvestorPlace

LivePerson, Amyris And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

March 16, 2023

U.S. stock futures traded mixed this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

The Latest Analyst Ratings for Esperion Therapeutics ↗

February 27, 2023

Via Benzinga

Looking Into Esperion Therapeutics's Return On Capital Employed ↗

February 22, 2023

Via Benzinga

Esperion Therapeutics's Earnings Outlook ↗

February 20, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

March 15, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

March 14, 2023

Tuesday's morning session saw 84 companies set new 52-week lows.

Via Benzinga

International Lipid Expert Panel (ILEP) Recommends Use of Bempedoic Acid Ahead of PCSK9 Inhibitors in Managing Lipid Disorders and Cardiovascular Risk

March 08, 2023

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023 ↗

March 07, 2023

Via Benzinga

DocuSign To Rally Around 25%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

March 07, 2023

Wells Fargo cut the price target for Cheniere Energy, Inc. (NYSE: LNG) from $236 to $230. Wells Fargo analyst Michael Blum maintained an Overweight rating. Cheniere Energy shares fell 4.8% to close at...

Via Benzinga

Nasdaq Rises 50 Points; Ciena Earnings Top Expectations ↗

March 06, 2023

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 50 points on Monday. The Dow traded up 0.16% to 33,444.91 while the NASDAQ rose 0.43% to 11,739.11. The S&P...

Via Benzinga

Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

March 06, 2023

Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

March 06, 2023

Via Benzinga

Dow Jumps Over 100 Points; BridgeBio Pharma Shares Spike Higher ↗

March 06, 2023

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Monday. The Dow traded up 0.42% to 33,531.77 while the NASDAQ rose 0.97% to 11,802.73. The S&P 500...

Via Benzinga

Nasdaq Rises 50 Points; US Factory Orders Down 1.6% In January ↗

March 06, 2023

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 50 points on Monday. Following the market opening Monday, the Dow traded up 0.24% to 33,471.14 while the NASDAQ rose...

Via Benzinga

Esperion Therapeutics Stock Is Diving: What's Going On? ↗

March 06, 2023

Esperion Therapeutics Inc (NASDAQ: ESPR) shares are trading lower Monday after the company published new data on its treatment aimed at

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 06, 2023

Via Benzinga

Why Hertz Global Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket ↗

March 06, 2023

Gainers Secoo Holding Limited (NASDAQ: SECO) rose 44% to $1.44 in pre-market trading after dipping over 31% on Friday.

Via Benzinga

Esperion Long Term Data On Cholesterol Medication's Ability To Cut Cardiovascular Risk Fails To Impress Investors ↗

March 06, 2023

Via Benzinga

Esperion Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

March 06, 2023

U.S. stock futures traded mixed this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients

March 04, 2023

Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion Launches New Scientific Website

February 24, 2023

Designed Specifically for the Scientific and Medical Communities, esperionscience.com Features Information about Esperion’s Landmark CLEAR Outcomes Study, Company Pipeline and More

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion to Participate in the Cowen 43rd Annual Healthcare Conference

February 23, 2023

From Esperion Therapeutics, Inc.

Via GlobeNewswire

CLEAR Outcomes Company Update Call: Detailed Results Discussion

February 22, 2023

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

February 21, 2023

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC

February 20, 2023

– NEXLETOL® (bempedoic acid) is the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint –

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

February 13, 2023

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion to Report Fourth Quarter and Full Year 2022 Financial Results February 21, 2023

February 07, 2023

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023 ↗

February 03, 2023

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.